Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Siglec-2

Siglec-2

Brief Information

Name:CD22
Target Synonym:B-Lymphocyte Cell Adhesion Molecule,SIGLEC2,BL-CAM,Siglec-2,Sialic Acid Binding Ig-like Lectin 2,B-cell receptor CD22,Sialic acid-binding Ig-like lectin 2,T-cell surface antigen Leu-14,CD22,CD22 Molecule,CD22 Antigen
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:40
Lastest Research Phase:Approved

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
SI2-HA2H7 Human Alexa Fluor 488-Labeled Human Siglec-2 / CD22 Protein, His TagStar Staining
SI2-HA2H7-structure
SI2-HA2H9 Human Alexa Fluor 555-Labeled Human Siglec-2 / CD22 Protein, His TagStar Staining
SI2-HA2H9-structure
MBS-K052 Human Human CD22-coupled Magnetic Beads
SI2-HP2H5 Human PE-Labeled Human Siglec-2 / CD22 Protein, His TagStar Staining
SI2-HP2H5-structure
SI2-H52H8 Human Human Siglec-2 / CD22 (176-687) Protein, His Tag (MALS verified)
SI2-H52H8-structure
SI2-H52H8-sds
CD2-HF254 Human FITC-Labeled Human Siglec-2 / CD22 Protein, Fc Tag
CD2-HF254-structure
CD2-HF254-sds
SI2-H82E3 Human Biotinylated Human Siglec-2 / CD22 Protein, His,Avitag™ (MALS verified)
SI2-H82E3-structure
SI2-H82E3-sds
CD2-H5253 Human Human Siglec-2 / CD22 Protein, Fc Tag (MALS verified)
CD2-H5253-structure
CD2-H5253-sds
CD2-C52H3 Canine Canine Siglec-2 Protein, His Tag
CD2-C52H3-structure
CD2-C52H3-sds
CD2-R52H3 Rat Rat Siglec-2 Protein, His Tag (MALS verified)
CD2-R52H3-structure
CD2-R52H3-sds
SI2-HF2H6 Human FITC-Labeled Human Siglec-2 / CD22 Protein, His Tag
SI2-HF2H6-structure
SI2-HF2H6-sds
SI2-H525a Human Human Siglec-2 / CD22 Protein, Llama IgG2b Fc Tag, low endotoxin
SI2-H525a-structure
SI2-H525a-sds
SI2-R52Ha Rhesus macaque Rhesus macaque Siglec-2 / CD22 Protein, His Tag
SI2-R52Ha-structure
SI2-R52Ha-sds
SI2-M52Ha Mouse Mouse Siglec-2 / CD22 Protein, His Tag
SI2-M52Ha-structure
SI2-M52Ha-sds
SI2-H82F8 Human Biotinylated Human Siglec-2 / CD22 Protein, Fc,Avitag™ (MALS verified)
SI2-H82F8-structure
SI2-H82F8-sds
CD2-H52H8 Human Human Siglec-2 / CD22 Protein, His Tag (MALS verified) DMF Filed
CD2-H52H8-structure
CD2-H52H8-sds

Part of Bioactivity data

SI2-HA2H7-Cell-based assay
 Siglec-2 CAR_T

5e5 of anti-CD22 CAR-293 cells were stained with 100 μL of 10 μg/mL of Alexa Fluor 488-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HA2H7) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). Alexa 488 signal was used to evaluate the binding activity (QC tested).

SI2-H52H8-SPR
Human_FcRn_Heterodimer_Protein_SPR

Monoclonal Anti-Human Siglec-2 Antibody, Human IgG1 captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human Siglec-2 (176-687), His Tag (Cat. No. SI2-H52H8) with an affinity constant of 0.121 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

SI2-H52H8-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Monoclonal Anti-Human CD22 Antibody, Human IgG1 on AHC Biosensor, can bind Human Siglec-2 / CD22 (176-687), His Tag (Cat. No. SI2-H52H8) with an affinity constant of 53 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

CD22,SIGLEC2,BL-CAM,SIGLEC-2,Siglec2,SIGLEC2FLJ22814

Background

B-cell receptor CD22 is also known as Sialic acid-binding Ig-like lectin 2 (Siglec-2), B-lymphocyte cell adhesion molecule (BL-CAM), T-cell surface antigen Leu-14, which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. CD22 mediates B-cell B-cell interactions, and may be involved in the localization of B-cells in lymphoid tissues. Siglec-2 / CD22 binds sialylated glycoproteins, one of which is CD45. Siglec2 / CD22 plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Moxetumomab pasudotox HA-22; GCR-8015; CAT-8015 Approved Astrazeneca Plc Lumoxiti United States Leukemia, Hairy Cell Innate Pharma 2018-09-13 Leukemia, Hairy Cell Details
Inotuzumab Ozogamicin WAY-207294; PF-5208773; CMC-544 Approved Pfizer Inc, Ucb Besponsa Mainland China Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Pfizer Investment Co Ltd 2017-06-28 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-CD22/CD19 monoclonal antibody-toxin conjugate Phase 1 Clinical Ut Southwestern Medical Center Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
RD-102 RD-102 Phase 1 Clinical Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse Details
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) Phase 1 Clinical Hrain Biotechnology Leukemia, Lymphoid Details
Anti-CD22 CAR T cell therapy (Shanghai GeneChem) Phase 1 Clinical Shanghai Genechem Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) Phase 1 Clinical Seattle Children'S Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
JCAR-018 JCAR-018 Phase 1 Clinical National Cancer Institute, Opus Bio Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Anti-CD22 CAR-T cell therapy (No. 307 Hospital) Phase 2 Clinical The Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital) Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) Phase 1 Clinical Shanghai Jiaotong University Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
anti-CD22-CAR-transduced T cells(Southwest Hospital) Phase 2 Clinical Southwest Hospital Leukemia; Lymphoma Details
Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell; Leukemia, B-Cell Details
Anti-CD22 CAR T cell therapy (Wuhan Bio-Raid) Phase 1 Clinical Wuhan Bio-Raid Biotechnology Lymphoma, B-Cell; Multiple Myeloma Details
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) Phase 2 Clinical People'S Liberation Army General Hospital Military Service Leukemia; Lymphoma Details
TAC-001 TAAC-001 Phase 1 Clinical Solid tumours Details
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) Phase 1 Clinical Stanford University Lymphoma, B-Cell Details
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Details
CTA-101 CTA-101 Phase 1 Clinical Nanjing Bioheng Biotech Co Ltd, Nanjing Medical University, Xuzhou Medical University (Xzmu) Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) Zhejiang University Details
JNJ-75348780 Phase 1 Clinical Janssen Research & Development Llc Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) HX-s001; YTS101; HX-s001/YTS101; HXYT-001 Phase 1 Clinical Beijing Qingyi Taike Pharmaceutical Technology Co Ltd, China Immunotech Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) Phase 2 Clinical Shenzhen University General Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) Phase 1 Clinical Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics) CT-120 Phase 2 Clinical Nanjing Iaso Biotherapeutics Co Ltd Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin Details
ThisCAR-T-22(Fundamenta Therapeutics) ThisCAR-T-22 Fundamenta Therapeutics Ltd Details
CD19x22 CAR T Cell Therapy (University Of Colorado Denver) Phase 1 Clinical University Of Colorado, Denver, Usa Lymphoma, Non-Hodgkin Details
Bispecific CD19/22 CAR T cells Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Details
IMJ-995 IMJ-995 Novartis Pharma Ag Details
CD22 CAR-T Cell Therapy (Hebei Senlang Biotechnology) Hebei Senlang Biological Technology Co Ltd Details
CD22-targeted CAR-T cell therapy (PersonGen Biomedicine) Persongen Biotherapeutics Details
BAY-1862864 BAY-1862864 Bayer AG Details
Anti-CD22-CAR T cell therapy (Kecellitics Biotech) Kecellitics Biotech Company Ltd Details
Suciraslimab SM-06; SM-03 Phase 3 Clinical Lonn Ryonn Pharma Ltd, Sinomab Bioscience Ltd Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin Details
CD22-CART Hrain Biotechnology Co Ltd Details
TRPH-222 CD22-4AP; TRPH-222; CAT-02-106 Catalent Inc Details
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) The University Of Texas MD Anderson Cancer Center Details
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) therapy (KK Women's and Children's Hospital) Phase 2 Clinical Kk Women'S And Children'S Hospital Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CAR-20-19-22 CAR-20-19-22 Phase 1 Clinical The Medical College Of Wisconsin Nonprofit Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
bispecific CD19/CD22 CAR T-cell therapy (University of Colorado) Phase 1 Clinical University Of Colorado Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
CD19/22 Bi-specific CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) 4SCAR19/22 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell; Leukemia, B-Cell Details
UCART-22 UCART-22 Phase 1 Clinical Cellectis Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Epratuzumab-cys-tesirine ADCT-602 Phase 2 Clinical Adc Therapeutics Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details
CART22-cells CART22-cells; JJO686 Phase 1 Clinical Novartis Pharma Ag, University Of Pennsylvania Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details
GC-022 GC-022; GC-022F Phase 2 Clinical Gracell Biotechnologies (Shanghai) Co Ltd Hematologic Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) Phase 1 Clinical The Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Details
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) 4SCAR-T Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Hematologic Neoplasms; Autoimmune Diseases Details
CD19/CD22 dual-target CAR-T (Yake biotechnology) Phase 2 Clinical Shanghai YaKe Biotechnology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Anti CD22 CAR-T cell therapy (Shanghai Yake Biotechnology) Phase 2 Clinical Shanghai YaKe Biotechnology Co Ltd, The First Affiliated Hospital Of Zhejiang University School Of Medicine, Beijing Gao Boren Hospital Co Ltd, Chengdu USino Technology Biology Co Ltd Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
UCART-20x22 UCART-20x22 Phase 1 Clinical Cellectis Lymphoma, Non-Hodgkin Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message